Publikationen 2003
Pregnancy-related changes in the longer-term management of HIV-infected women in Europe
European Collaborative Study
Eur J Obstet Gynecol Reprod Biol. 2003 Nov 10;111(1):3-8
Antifungal combinations against Candida albicans biofilms in vitro
Bachmann SP, Ramage G, VandeWalle K, Patterson TF, Wickes BL, Lopez-Ribot JL
Antimicrob Agents Chemother 2003;47(11):3657-9
Mortality in the Swiss HIV Cohort Study (SHCS) and the Swiss general population
Jaggy C, von Overbeck J, Ledergerber B, Schwarz C, Egger M, Rickenbach M, Furrer H.J., Telenti A, Battegay M, Flepp M, Vernazza P, Bernasconi E, Hirschel B
Lancet 2003;362(9387):877-8.
Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial
Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vibhagool A, Wicharuk S, Ruxrungtham K, Furrer H, Cooper D, Hirschel B, Bernasconi E, Cavassini M, Ebnother C, Fagard C, Genne D, Khanna N, Perrin L, Phanupak P, Ubolyam S, Vernazza P, Yerly S; Swiss HIV Cohort Study
AIDS 2003;17(15):F33-7
Diagnostik der latenten Tuberkulose im neuen Millennium
Hoffmann M, Vernazza P, Fierz W
SMF 2003; 50:1244-1247
CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study
Kaufmann G R, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M
AIM 2003; 163:2187-2195
Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1–Infected Patients: The MaxCmin1 Trial
Dragsted U, Gerstoft J, Pedersen C, Peters B,Duran A,Obel N, Castagna A, Cahn P, Clumeck N, Bruun J, Benetucci J, Hill A, Cassetti I, Vernazza P, Youle M, Fox Z, and Lundgren J,1 for the MaxCmin1 Trial Groupa
JID 2003; 188:635–42
Prevalence of Unsafe Sexual Behavior Among HIV-Infected Individuals: The Swiss HIV Cohort Study
Wolf K, Young J, Rickenbach M, Vernazza P, Flepp M, Furrer H, Bernasconi E, Hirschel B, Telenti A, Weber R, Bucher H, and the Swiss HIV Cohort Study
JAIDS 2003; 33: 494-499
A controlled trial of granulocyte macrophage-colony stimulating factor during interruption of HAART
Fagard C, Le Braz M, Günthard H, Hirsch H, Egger M, Vernazza P, Bernasconie E, Telenti A, Ebnöther C, Oxenius A, Perneger T, Perrin L, Hirschel B and the Swiss HIV Cohort Study
AIDS 2003; 17(10):1487-1492
Lopinavir/Ritonavir: A Review of its Use in the Management of HIV Infection
Cvetkovic R, Goa K, Vernazza P et al.
Drugs 2003; 63(6): 769-802
A Prospective Trial of Structured Treatment Interruptions in Human Immunodeficiency Virus Infection
Fagard C, Oxenius A, Günthard H, Garcia F, Le Braz M, Mestre G, Vernazza P et al.
Arch Intern Med. 2003;163:1220-1226
Mitochondrial DNA and sperm quality in patients under antiretroviral therapy
Diehl S, Vernazza P, Trein A, Schnaitmann E, Grimbacher B, Setzer B, Walker U
AIDS 2003; 17(3):450-451
High risk behaviour and fertility desires among heterosexual HIV-positive patients with a serodiscordant partner – two challenging issues
Panozzo L, Battegay M, Friedl A, Vernazza P,
SMW 2003;133:124–127
Antiretroviral therapy to reduce the sexual transmission of HIV
Taylor S, Boffito M, Vernazza P
J HIV Ther. 2003;8(3):55-66
